Cyduct backs precision molecular testing as breast health market evolves

Cyduct Diagnostics said the market is moving toward precision molecular testing and personalized health insights as cancer screening technology gains traction. The company framed the shift as a sign that molecular tools could become a bigger part of preventive care and breast health management.

Why it matters: - Cyduct Diagnostics is positioning its breast health platform around a market shift toward earlier, more personalized molecular detection. - The company argues that precision testing could complement imaging and standard screening, not replace them. - Broader adoption of molecular screening could expand how clinicians assess risk and detect disease-related biological changes earlier.

What happened: - Cyduct Diagnostics, Inc. said it welcomes the accelerating move toward precision testing and personalized molecular insights in cancer screening and early detection. - The company issued the statement from Westport, Connecticut, on August 10, 2026. - Chief Executive Officer Dom Gatto said the future of screening is an integrated model that combines imaging, molecular testing, risk assessment and clinical follow-up.

The details: - Cyduct said it is developing technologies to support earlier detection and more precise breast health management. - The company said its proteomic breast health platform is being developed as scientific innovation advances and regulatory and clinical pathways evolve. - Cyduct said recent approvals of molecular screening technologies show these approaches can move into mainstream medicine when backed by rigorous clinical evidence and a defined intended use. - The company said major healthcare companies are expanding portfolios to include multiple screening modalities. - Gatto said no single screening method will meet the needs of every patient. - Gatto said Cyduct’s long-term objective is to help bring precision medicine to the global breast health market. - Gatto said the company wants to move the search for meaningful biological changes closer to the earliest stages of disease. - Gatto said Cyduct intends to advance breast health assessment closer to the ducts, where most breast cancers begin, and provide more personalized molecular information. - Cyduct said additional product information will be available on the company’s website at company website.

Between the lines: - The statement reads like a market-positioning update as much as a product update. - Cyduct is tying its story to broader momentum in precision diagnostics to signal relevance in a fast-moving category. - The company also uses the release to reinforce a long-term thesis: earlier, more targeted testing could reshape preventive breast care.

What's next: - Cyduct said more information on its product line will appear on its website. - The company also included standard forward-looking language, warning that plans, expectations and future performance could change. - Cyduct said its Annual Report and other OTC Markets filings contain additional risk disclosures.